| Kym C Gohn, DO | |
|
3016 W. Wackerly St., Midland, MI 48640-6960 | |
| (989) 631-6730 | |
| (989) 631-4398 |
| Full Name | Kym C Gohn |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 3016 W. Wackerly St., Midland, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447459011 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | OS015655 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midmichigan Obstetrics And Gynecology Pc | 1456392042 | 5 |
News Archive
Individuals who suffer from migraine headaches appear to have a hyper-excitable visual cortex researchers at the Universities of Birmingham and Lancaster suggest.
The first comprehensive analysis of the clinical effects of genetic mutations involved in Rett syndrome will enable affected families to receive a more accurate indication of their child's prognosis.
Socioeconomic, geographic and demographic factors all played critical roles in the risk of SARS-CoV-2 infection and COVID-19 mortality among Orange County residents last year, according to a study led by the University of California, Irvine.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
› Verified 7 days ago
| Entity Name | Midmichigan Obstetrics And Gynecology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346313277 PECOS PAC ID: 1456392042 Enrollment ID: O20050513000089 |
News Archive
Individuals who suffer from migraine headaches appear to have a hyper-excitable visual cortex researchers at the Universities of Birmingham and Lancaster suggest.
The first comprehensive analysis of the clinical effects of genetic mutations involved in Rett syndrome will enable affected families to receive a more accurate indication of their child's prognosis.
Socioeconomic, geographic and demographic factors all played critical roles in the risk of SARS-CoV-2 infection and COVID-19 mortality among Orange County residents last year, according to a study led by the University of California, Irvine.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kym C Gohn, DO 3016 W. Wackerly St., Midland, MI 48640-6960 Ph: (989) 631-6730 | Kym C Gohn, DO 3016 W. Wackerly St., Midland, MI 48640-6960 Ph: (989) 631-6730 |
News Archive
Individuals who suffer from migraine headaches appear to have a hyper-excitable visual cortex researchers at the Universities of Birmingham and Lancaster suggest.
The first comprehensive analysis of the clinical effects of genetic mutations involved in Rett syndrome will enable affected families to receive a more accurate indication of their child's prognosis.
Socioeconomic, geographic and demographic factors all played critical roles in the risk of SARS-CoV-2 infection and COVID-19 mortality among Orange County residents last year, according to a study led by the University of California, Irvine.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
› Verified 7 days ago
Mrs. Kelly Marie Hamilton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4401 Campus Ridge Dr Ste Ll110, Midland, MI 48640 Phone: 989-837-9400 Fax: 989-837-9410 | |
Paula Reif Headbloom, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3306 Thornbrook Ct, Midland, MI 48640 Phone: 989-859-1233 Fax: 989-631-4960 | |
Mr. Mark Edward English Jr., MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4401 Campus Ridge Dr Ste Ll110, Midland, MI 48640 Phone: 989-837-9400 | |
Cheryl Dwyer, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4320 Campus Ridge Drive, Midland, MI 48640 Phone: 989-839-3170 Fax: 989-839-1840 | |
Dr. Elvira Mikhailovna O'brien, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4401 Campus Ridge Dr Ste Ll110, Midland, MI 48640 Phone: 989-837-9400 Fax: 989-837-9410 | |
Dr. David Allen Junge, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4009 Orchard Drive, Suite #3025, Midland, MI 48640 Phone: 989-631-7913 Fax: 989-631-5798 | |
Dr. Sandeep Sambrani Rao, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4401 N Campus Ridge Dr, #b2200, Midland, MI 48640 Phone: 989-837-9400 |